Gastroenterology, Hepatology and Nutrition


Contact Information
Gastroenterology, Hepatology & Nutrition
Joel E. Lavine, MD, PhD
(212) 342-2962
Lubna Shamsi, MPH
(212) 305-5831
(212) 342-5756
  • Empire Clinical Research Investigator Program for Pediatric Obesity Education and Research, New York State Department of Health/NYP. Project Director: M. Rosenbaum; Co-Director: Joel Lavine, MD. Direct support: $1,260,332 (total for two years). (2015-18)
  • STOPNASH National Clinical Research Conference, NIDDK R13 DK107243-01. Direct support funds: $25,000. Joel Lavine, MD (2015) 
  • Contribution of Organ Size to Adaptive Thermogenesis during Caloric Restriction. Wei Shen, MD (NIH grant 1R01 1AG045761-01)
  • Prevalence of Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) in NYC: Fatty liver disease is the most common cause of liver disease in the pediatric population and is closely linked to the rise in obesity. Unfortunately, the diagnosis and staging of the NAFLD can only be made with liver biopsy, so it has been difficult to determine its true prevalence. This study will be using autopsy data from pediatric patients who succumbed to an accidental death to determine the prevalence of fatty liver disease in the New York City area. The project is funded by the New York Obesity Nutrition Research Center. Ali Mencin, MD (NY Obesity Nutrition Research Center - SLRHC CU11-0598)
  • Sex Differences in Statural Growth Impairment in Pediatric Patients with Crohn's Disease: This study will determine the impact of inflammation on hormones and sex-specific growth impairment in Crohn's disease. The study will develop a predictive model for each sex to identify patients with Crohn's disease at high risk for developing growth impairment refractory to standard therapeutic approaches based on a panel of serum and urine biomarkers and clinical variables. Neera Gupta, MD, MAS (NIDDK, R01HD075929)
  • Statural growth in pediatric patients with ulcerative colitis: This study evalutes growth in patients with ulcerative colitis. Neera Gupta, MD, MAS (NIDDK, RO1 pending)
  • Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study: We are a participating site in this multicenter clinical trial that will determine the response to standardized medical therapy and identify clinical, genetic, and immune markers that predict response to therapy in pediatric patients with ulcerative colitis. Neera Gupta, MD, MAS (NIDDK - U01DK095745)
  • Non-alcoholic fatty liver disease (NAFLD): To study the natural history, etiopathogenesis, epidemiology, histopathology imaging and treatment with xenobiotics of NAFLD. Joel Lavine, MD, PhD (NICHD-5R01 HD062489-02)
  • Role of Enteric nervous system and predisposition to Crohn's disease, Ulcerative Colitis and Necrotizing Enterocolitis: This grant aims to examine the effects of the density of enteric innervation on intestinal permeability, the innate immune system and the adaptive immune system. Kara Margolis, MD (NIH K08 - PA-11-193)
  • Role of gastrointestinal disorders in children with autism: This grant aims to examine the effects of the density of enteric innervation on intestinal permeability, the innate immune system and the adaptive immune system. Kara Margolis, MD (AGEA - CU11-3510)
  • FISH OIL FOR THE TREATMENT OF NON-ALCHOLIC FATTY LIVER DISEASE (NAFLD): The goal of this pediatric study is to determine if supplements of n-3 LCPUFA can improve elevated liver enzymes, plasma lipid levels, as well as attenuate insulin resistance in patients with fatty liver disease. Diana Volpert, MD, FAAP (GlaxoSmithKline)
  • Clinical Research on Nonalcoholic Fatty Liver Disease: These studies examine the natural history, etiopathogenesis, epidemiology, histopathology, imaging, treatment and development of biomarkers in fatty liver disease in children and adults. Joel Lavine, MD, PhD (NIH - 5U01DK061734-11)
  • A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease: This is a multicenter longitudinal study examining the safety and efficacy of biological modifiers in inflammatory bowel disease. Joel Lavine, MD, PhD (C0168Z02; CRD1 CU11-2532)
  • NAFLD Altered Drug Metabolism study: This study examines the metabolism of certain xenobiotics in children with biopsy proven NASH and matched controls. Joel Lavine, MD, PhD (NIH - NICHD- 5R01HD062489-02)
  • Intestinal Taste Perception and the Metabolic Syndrome: Sarah Taylor, MD will be working in the laboratory of Dr. Charles Zuker, PhD investigating the role of taste sensing in the mouse intestine. Sarah Taylor (NICHD/Pediatric National Scientific Development Award - PSDP / NICHD/K12HD000850-28)
  • The role of peripherally produced serotonin in energy metabolism: Dana Goldner will be working under the guidance of Dr. Gerard Karsenty, MD, PhD, investigating the role of peripherally produced serotonin in glucose and lipid metabolism. Dana Goldner (NICHD/Pediatric National Scientific Development Award - PSDP / NICHD/K12HD000850-28)
  • The trial, called Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children (CyNCh),will enroll 160 boys and girls ages 8 to 17 with nonalcoholic fatty liver disease (NAFLD). The participants will receive cysteamine or placebo by mouth twice a day for a year. There are no weight cutoffs or percentiles for the children participating in CyNCh. However, more than 90 percent of the children are expected to be overweight or obese. Participants need a baseline biopsy that confirms severe NAFLD to be eligible for the study. Children with poorly managed diabetes, heart disease, and other chronic liver diseases will be excluded. FUNDED BY THE NIDDK. CONTACT JOEL LAVINE.
  • A Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Pediatric Subjects Aged 6 Years to < 18 Years with Functional Constipation. Julie Khlevner, MD (Industry Sponsored Grant by Sucampo)
  • "A Multi-Center Study of the Prevalence of Known Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C-Sucrose Breath Test in Children with Chronic Diarrhea or Chronic Abdominal Pain." Julie Khlevner, MD (Industry sponsored Grant by QOL Medical)
  • Advancing Non-invasive Testing for Pediatric Nonalcoholic Fatty Liver Disease, Research/New York Obesity Nutrition Research Center, Pilot and Feasibility Program, Role: PI. The goal of this project is to collect pilot data on the ability of non-invasive ultrasound and magnetic resonance methods to quantify hepatic steatosis in children age 4-18 years and to create a bio-repository of blood and stool samples for future analysis of mechanisms that link adiposity, NAFLD, and adverse cardio-metabolic outcomes in children. Jennifer Woo Baidal, MD, MPH (2015)
  • Early Life Risk Factors for Nonalcoholic Fatty Liver Disease, Research/Academic Pediatric Association, NIDDK-funded RAPID initiative, Role: PI. The goal of this research is to study the longitudinal relationship of early childhood risk factors for obesity with serum ALT levels in mid-childhood, identify new modifiable nutritional risk factors for elevated serum ALT levels in mid-childhood, and to ascertain the role of child adiposity and body composition in these relationships. Jennifer Woo Baidal, MD, MPH (2014-15)